Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

PURPOSE: Nilotinib is a second-generation oral tyrosine kinase inhibitor (TKI) with superior efficacy compared with imatinib mesylate in the treatment of chronic phase chronic myelogenous leukemia (CML). Calcium carbonate is commonly used as a source of calcium supplementation or as antacid to ameli...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tawbi, Hussein A., Tran, An L., Christner, Susan M., Lin, Yan, Johnson, Matthew, Mowrey, Emily, Appleman, Leonard R., Stoller, Ronald, Miller, Brian M., Egorin, Merrill J., Beumer, Jan H.
Format:	Artigo
Language:	Inglês
Published:	2013
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3818249/ https://ncbi.nlm.nih.gov/pubmed/24036846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2283-x
Tags:	Add Tag No Tags, Be the first to tag this record!

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

Similar Items